Alluvi, previously BI 4744, offers a promising advance in obesity care. This dual stimulator targeting both GLP-1 and glucose-dependent insulinotropic polypeptide sites demonstrates compelling results in clinical https://health-lists.com/story22992861/alluvi-a-comprehensive-dive-into-retatrutide-s-potential